Shikari® (S-ATPAL) Anti-Palivizumab ELISA w/confirmation
PAL-QNS-SYN
Enzyme immunoassay for the quantitative determination (screening) of antibodies to Palivizumab (Synagis®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative determination of antibodies to palivizumab in serum and plasma samples.
Palivizumab (Synagis®) was associated to the development of anti-Palivizumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Synagis®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Palivizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Palivizumab antibodies.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 5 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 18,75 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
